Ionis Pharmaceuticals IncIONS
ASignal's systematic analysis rates IONS as Bearish.
Reflects the latest available analysis · analyzed Aug 26, 2026
The case on IONS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- High current ratio (7.89x) indicates strong short-term liquidity
- Positive MACD histogram expansion suggests recent bullish momentum
- Cash position ($2.10B) is substantial relative to debt
- RSI at 76.32 indicates overbought conditions
- Negative gross, operating, and net margins
- High debt-to-equity ratio (4.98x)
- Negative free cash flow (-$346.76M)
- Negative revenue growth (down 40.7% YoY)
- Extremely high forward PEG ratio (27.33x) and negative EV/EBITDA (-18.38x)
See the full verdict on IONS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes IONS
Most investors never get a second opinion, let alone several. ASignal runs IONS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.